[go: up one dir, main page]

ECSP099767A - Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas - Google Patents

Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas

Info

Publication number
ECSP099767A
ECSP099767A EC2009009767A ECSP099767A ECSP099767A EC SP099767 A ECSP099767 A EC SP099767A EC 2009009767 A EC2009009767 A EC 2009009767A EC SP099767 A ECSP099767 A EC SP099767A EC SP099767 A ECSP099767 A EC SP099767A
Authority
EC
Ecuador
Prior art keywords
treatment
proliferative
pirimidina
morfolin
piridin
Prior art date
Application number
EC2009009767A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Richard Ducray
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP099767A publication Critical patent/ECSP099767A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de pirimidina de Fórmula I, o una sal farmacéuticamente aceptable de los mismos, en donde A1, A2 A3, R1, n, R2, R3 y R4 son tal como se definen en la memoria descriptiva. La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para su uso como un agente antiproliferativo en la prevención o tratamiento de tumores u otras afecciones proliferativas que son sensibles a la inhibición de las quinasas EphB4.
EC2009009767A 2007-04-27 2009-11-27 Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas ECSP099767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301001 2007-04-27
EP07301002 2007-04-27

Publications (1)

Publication Number Publication Date
ECSP099767A true ECSP099767A (es) 2009-12-28

Family

ID=39739252

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009767A ECSP099767A (es) 2007-04-27 2009-11-27 Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas

Country Status (11)

Country Link
US (1) US20090036440A1 (es)
EP (1) EP2150545A1 (es)
JP (1) JP2010525047A (es)
KR (1) KR20100017441A (es)
AU (1) AU2008244026A1 (es)
CA (1) CA2687943A1 (es)
CO (1) CO6241117A2 (es)
EC (1) ECSP099767A (es)
NZ (1) NZ581397A (es)
RU (1) RU2009143753A (es)
WO (1) WO2008132505A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010789A2 (en) 2007-07-16 2009-01-22 Astrazeneca Ab Pyrimidine derivatives 934
US8343966B2 (en) * 2008-01-11 2013-01-01 Novartis Ag Organic compounds
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
TWI681952B (zh) 2011-04-22 2020-01-11 美商標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
ES2882954T3 (es) 2014-12-16 2021-12-03 Signal Pharm Llc Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel
US9796685B2 (en) 2014-12-16 2017-10-24 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
CN110357832B (zh) * 2019-07-08 2022-03-15 武汉大学 一种芳香胺类化合物及EphB4激酶抑制剂及其衍生物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531853A (en) * 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
EP1904457B1 (en) * 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
US20080214558A1 (en) * 2007-03-01 2008-09-04 Supergen, Inc. Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors

Also Published As

Publication number Publication date
EP2150545A1 (en) 2010-02-10
WO2008132505A1 (en) 2008-11-06
AU2008244026A1 (en) 2008-11-06
CO6241117A2 (es) 2011-01-20
JP2010525047A (ja) 2010-07-22
US20090036440A1 (en) 2009-02-05
CA2687943A1 (en) 2008-11-06
RU2009143753A (ru) 2011-06-10
KR20100017441A (ko) 2010-02-16
NZ581397A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
CO6290670A2 (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas